Brain metastasis is a poor prognostic predictor of lung cancer,8, 17 and the efficiency of first‐generation EGFR‐TKIs combined with bevacizumab for EGFR mutation patients with brain metastasis remains controversial;13, 18 therefore, this study aimed to determine the efficacy and toxicities of osimertinib plus bevacizumab in patients with NSCLC with brain metastasis harboring EGFR‐activating mutations. The gene discussed is EGFR; the disease is lung cancer.